

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF MEDICAL OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**,” together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Wu Zhuli (吳諸麗) (“**Dr. Wu**”) was appointed as a Chief Medical Officer of the Group with effect from June 9, 2025, responsible for the establishment and management of the Company’s clinical team, clinical trial research, clinical development and registration. Dr. Wu is based in China and reports directly to Dr. Tian Wenzhi, the founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company.

Dr. Wu has over 13 years of extensive experience in the clinical development of new drugs in hematology, oncology and immunology. Prior to joining the Group, Dr. Wu worked at renowned pharmaceutical companies, including Janssen Pharmaceuticals, Roche, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (“**Fosun Pharma**”). From 2018 to 2025, Dr. Wu served as the senior vice president and chief medical officer (oncology) for China at Fosun Pharma’s R&D center, where she led clinical development strategies for 16 innovative molecules. Under her leadership, over 40 investigational new drug (IND) applications were approved, five new drug applications (NDA) were submitted, with three successfully approved, and three breakthrough therapy

designations were awarded. Luvometinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, whose development she led, achieved market launch at a groundbreaking pace, becoming China's first local innovative drug for the treatment of histiocytic proliferative diseases/histiocytic tumors and pediatric neurofibromatosis type 1-associated plexiform neurofibroma, addressing a critical gap in clinical treatment. Beyond her corporate leadership, Dr. Wu serves as a member of the Third Chinese Society of Clinical Oncology (CSCO) Clinical Trials Professional Committee (中國臨床腫瘤學會第三屆臨床試驗專業委員會) and a member of the Anti-cancer Drug Clinical Research Professional Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) (中國醫藥創新促進會抗腫瘤藥物臨床研究專業委員會).

Dr. Wu received clinical medicine education at Peking University (北京大學) and clinical oncology at Peking University Cancer Hospital, (北京大學腫瘤醫院) in China from September 2001 to July 2009.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, June 9, 2025

* *for identification purposes only*

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.